Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Common Equity (2016 - 2025)

Historic Common Equity for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $503.0 million.

  • Viridian Therapeutics, Inc.\DE's Common Equity fell 2890.84% to $503.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $503.0 million, marking a year-over-year decrease of 2890.84%. This contributed to the annual value of $671.6 million for FY2024, which is 5194.7% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Common Equity of $503.0 million as of Q3 2025, which was down 2890.84% from $515.2 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Common Equity registered a high of $707.5 million during Q3 2024, and its lowest value of $98.9 million during Q2 2021.
  • Its 5-year average for Common Equity is $379.8 million, with a median of $395.1 million in 2022.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Common Equity skyrocketed by 87229.83% in 2021 and then crashed by 3066.72% in 2023.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Common Equity stood at $187.7 million in 2021, then skyrocketed by 110.46% to $395.1 million in 2022, then grew by 11.89% to $442.0 million in 2023, then surged by 51.95% to $671.6 million in 2024, then dropped by 25.11% to $503.0 million in 2025.
  • Its Common Equity was $503.0 million in Q3 2025, compared to $515.2 million in Q2 2025 and $604.5 million in Q1 2025.